Neurocrine Biosciences
Yahoo Finance • 2 days ago
Neurocrine Biosciences Reports Third-Quarter 2026 Financial Results
Total Third-Quarter 2026 Revenue Grew 41% Year-Over-Year to $1.1 Billion INGREZZA® (valbenazine) 2026 Net Sales Guidance Raised to $2.9 to $2.925 Billion SAN DIEGO, Nov. 2, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX)... Full story
Yahoo Finance • 10 days ago
Neurocrine Biosciences Presents New Analysis Establishing Benchmark for Clinically Meaningful Change in Overall Health Reported by Patients with Tardive Dyskinesia
New analysis establishes a 6-point increase on the EQ Visual Analogue Scale as a threshold for clinically meaningful change in overall health ratings in patients with tardive dyskinesia treated with INGREZZA®(valbenazine) capsules The 6-po... Full story
Yahoo Finance • 13 days ago
Neurocrine Biosciences (NBIX) Starts Phase 2 Alzheimer’s Trial
Neurocrine Biosciences (NasdaqGS:NBIX) has begun a Phase 2 trial of NBI-1117567 in adults with mild to moderate Alzheimer's disease. The study evaluates an orally administered muscarinic receptor agonist aimed at treating cognitive impairm... Full story
Yahoo Finance • 17 days ago
Oppenheimer updates its top 50 buy list, rotating away from big banks
[Trading charts background] da-kuk/E+ via Getty Images Oppenheimer recently overhauled its top 50 large-cap buy list this month, executing a rotation in the financials sector (XLF [https://seekingalpha.com/symbol/XLF]) by swapping out leg... Full story
Yahoo Finance • 19 days ago
Neurocrine Biosciences (NBIX) Stock Trades Below Fair Value On Earnings
Neurocrine Biosciences shares have pulled back in recent weeks after a multi year climb, which puts a spotlight on whether the current price around US$135 still lines up with what the business is earning. For anyone tracking the stock, the... Full story
Yahoo Finance • 24 days ago
Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2026 Financial Results
Conference Call and Webcast Scheduled for Monday, November 2 SAN DIEGO, Oct. 12, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its third quarter 2026 financial results conference ca... Full story
Yahoo Finance • last month
Neurocrine Biosciences Appoints Eiry W. Roberts, M.D., as Chief Medical Officer
SAN DIEGO, Sept. 28, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that Eiry W. Roberts, M.D., who previously served as Neurocrine's Chief Medical Officer and currently serves as a Strategic Advisor, will... Full story
Yahoo Finance • 2 months ago
Did Nxera’s Alzheimer’s Milestone and IND Progress Just Shift Neurocrine Biosciences' (NBIX) Investment Narrative?
Nxera Pharma recently announced that its partner Neurocrine Biosciences received FDA IND acceptance for a Phase 2 trial of NBI-1117567, an investigational oral muscarinic M1-preferring agonist for Alzheimer's cognition, triggering a US$10,... Full story
Yahoo Finance • 2 months ago
NBIX vs. TEVA: Which Drugmaker Is the Better Investment?
Both Neurocrine Biosciences NBIX and Teva Pharmaceuticals TEVA operate in the pharmaceutical sector, focusing on specialty medicines and treatments for serious health conditions. NBIX focuses on neuroscience, with growth primarily led by... Full story
Yahoo Finance • 3 months ago
Neurocrine Biosciences Commences Phase 1 First-in-human Clinical Study Of NBIP-'1968
(RTTNews) - Friday, Neurocrine Biosciences, Inc. (NBIX) announced the commencement of a Phase 1 first-in-human clinical study, evaluating the safety and tolerability of NBIP-'1968 for the treatment of obesity. NBIP-'1968 is an investigati... Full story
Yahoo Finance • 3 months ago
Neurocrine Biosciences (NBIX) Lifts INGREZZA Guidance, Is The Pullback A Bargain?
Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Neurocrine Biosciences (NBIX) stock is in focus after the company reported second quarter 2026 r... Full story
Yahoo Finance • 3 months ago
Neurocrine Biosciences Announces Key Leadership Hiring, Promotions
SAN DIEGO, July 23, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the appointment of three Senior Vice Presidents, further strengthening its leadership team as the company executes its next phase of growt... Full story
Yahoo Finance • 3 months ago
Neurocrine Biosciences (NBIX) Appoints Samir Siddhanti As Chief Business Officer
Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Neurocrine Biosciences (NasdaqGS:NBIX) has appointed Samir Siddhanti as Chief Business Officer. Siddhanti will also join th... Full story
Yahoo Finance • 4 months ago
Oppenheimer Picks Apple, Amazon, Alphabet as Top Stock Buys
This article first appeared on GuruFocus. Oppenheimer said investors may want to use the recent pullback in higher-beta stocks to selectively add equity exposure rather than adopt a defensive stance. The firm said recent market action re... Full story
Yahoo Finance • 4 months ago
Zacks.com featured highlights include NVIDIA, Neurocrine Biosciences and Ball
For Immediate Release Chicago, IL – July 16, 2026 – Stocks in this week's article are NVIDIA Corp. NVDA, Neurocrine Biosciences, Inc. NBIX and Ball Corp. BALL. NVIDIA & 2 Best Earnings Growth Stocks to Buy for 2H 2026 Earnings growth is... Full story
Yahoo Finance • 4 months ago
Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2026 Financial Results
Conference Call and Webcast Scheduled for Thursday, July 30 SAN DIEGO, July 9, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its second quarter 2026 financial results conference cal... Full story
Yahoo Finance • 4 months ago
Neurocrine Biosciences (NBIX): High Growth NASDAQ Stocks to Buy Now
Neurocrine Biosciences Inc. (NASDAQ:NBIX) is one of the high growth NASDAQ stocks to buy now. On June 15, Neurocrine Biosciences presented two-year Phase 3 data at ENDO 2026 showing that CRENESSITY (crinecerfont) improves growth outcomes i... Full story
Yahoo Finance • 4 months ago
Best Value Stocks to Buy for June 24th
Here are three stocks with buy rank and strong value characteristics for investors to consider today, June 24: Navigator Holdings Ltd. NVGS: This global operator of a fleet of liquefied gas carriers carries a Zacks Rank #1, and has witnes... Full story
Yahoo Finance • 5 months ago
Weekly Buzz: SPRO, ABBV Get FDA Nod, NMRA Halts KOASTAL; ENGN Cuts Jobs; BIIB Acquires RayThera
(RTTNews) - This week, the biotech sector saw FDA approvals, alongside study halts, layoffs, strategic collaborations, acquisitions, deal closures, and encouraging data readouts. Positive clinical readouts spanning therapeutic areas inclu... Full story
Yahoo Finance • 5 months ago
Is Neurocrine Biosciences, Inc. (NBIX) A Good Stock To Buy Now?
Is NBIX a good stock to buy? We came across a bullish thesis on Neurocrine Biosciences, Inc. on TradersPro's Substack. In this article, we will summarize the bulls' thesis on NBIX. Neurocrine Biosciences, Inc.'s share was trading at $159.7... Full story